S&P 500

6.040,04

1,10%

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Exscientia PLC (EXAI)
Exscientia PLC (EXAI) Notícias

EXAI

Exscientia (EXAI)

Exscientia PLC

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:EXAI

1 2 3 4 5 6 7 8 9 10 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
02/12/2024	10:39	Edgar (US Regulatory)	Form 15-12G - Securities registration termination [Section 12(g)]	NASDAQ:EXAI	Exscientia PLC
22/11/2024	22:00	Edgar (US Regulatory)	Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]	NASDAQ:EXAI	Exscientia PLC
20/11/2024	12:01	Edgar (US Regulatory)	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments	NASDAQ:EXAI	Exscientia PLC
20/11/2024	11:20	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:EXAI	Exscientia PLC
20/11/2024	09:00	GlobeNewswire Inc.	Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery	NASDAQ:EXAI	Exscientia PLC
24/10/2024	17:00	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:EXAI	Exscientia PLC
16/10/2024	22:49	Business Wire	Exscientia franchit des étapes importantes pour deux de ses programmes dans le cadre de sa collaboration avec Sanofi	NASDAQ:EXAI	Exscientia PLC
16/10/2024	22:35	Business Wire	Exscientia erreicht Meilensteine für zwei Programme im Rahmen der Zusammenarbeit mit Sanofi	NASDAQ:EXAI	Exscientia PLC
16/10/2024	08:00	Business Wire	Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration	NASDAQ:EXAI	Exscientia PLC
09/10/2024	16:25	Business Wire	Exscientia präsentiert auf der ENA 2024 neue präklinische Daten für KI-gestützte LSD1- und MALT1-Inhibitoren	NASDAQ:EXAI	Exscientia PLC
09/10/2024	16:25	Business Wire	Exscientia présentera de nouvelles données précliniques pour les inhibiteurs de la LSD1 et du MALT1 conçus par l'IA à l'ENA 2024	NASDAQ:EXAI	Exscientia PLC
09/10/2024	08:00	Business Wire	Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024	NASDAQ:EXAI	Exscientia PLC
30/08/2024	09:57	Edgar (US Regulatory)	Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]	NASDAQ:EXAI	Exscientia PLC
28/08/2024	13:11	Business Wire	Exscientia wird auf der 22nd Annual Global Healthcare Conference Präsentation durchführen	NASDAQ:EXAI	Exscientia PLC
28/08/2024	13:11	Business Wire	Exscientia participera à la 22e conférence annuelle de Morgan Stanley sur les soins médicaux dans le monde	NASDAQ:EXAI	Exscientia PLC
28/08/2024	08:00	Business Wire	Exscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference	NASDAQ:EXAI	Exscientia PLC
15/08/2024	08:00	Business Wire	Exscientia Business Update for Second Quarter and First Half 2024	NASDAQ:EXAI	Exscientia PLC
09/08/2024	06:44	IH Market News	TSMC July Revenue Surges 45%, Nasdaq Accelerates Penny Stock Delistings, Moody’s Downgrades Intel to BAA1, and More	NASDAQ:EXAI	Exscientia PLC
08/08/2024	08:39	GlobeNewswire Inc.	Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities	NASDAQ:EXAI	Exscientia PLC
18/07/2024	13:36	Business Wire	Exscientia erwirbt volle Rechte an potenziellem CDK7-Inhibitor der Spitzenklasse vor der Veröffentlichung von Phase-1-Dosis-Eskalationsdaten	NASDAQ:EXAI	Exscientia PLC
18/07/2024	11:20	Business Wire	Exscientia acquiert les droits complets d’un inhibiteur potentiel de CDK7, le meilleur de sa catégorie, avant la publication des données de dose croissante de phase 1	NASDAQ:EXAI	Exscientia PLC
18/07/2024	08:00	Business Wire	Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout	NASDAQ:EXAI	Exscientia PLC
10/07/2024	18:44	Business Wire	Exscientia lance une plateforme AWS optimisée par l'IA pour promouvoir la découverte de médicaments	NASDAQ:EXAI	Exscientia PLC
10/07/2024	16:13	Business Wire	Exscientia bringt KI-gestützte AWS-Plattform zur Verbesserung der Arzneimittelforschung auf den Markt	NASDAQ:EXAI	Exscientia PLC
10/07/2024	08:00	Business Wire	Exscientia Launches AWS AI-powered Platform to Advance Drug Discovery	NASDAQ:EXAI	Exscientia PLC
25/06/2024	06:45	PR Newswire (US)	EXAI LAWSUIT ALERT: The Gross Law Firm Notifies Exscientia plc Investors of a Class Action Lawsuit and Upcoming Deadline	NASDAQ:EXAI	Exscientia PLC
20/06/2024	06:45	PR Newswire (US)	Exscientia plc Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before June 25, 2024 to Discuss Your Rights - EXAI	NASDAQ:EXAI	Exscientia PLC
17/06/2024	06:45	PR Newswire (US)	Shareholders that lost money on Exscientia plc(EXAI) Urged to Join Class Action - Contact The Gross Law Firm to Learn More	NASDAQ:EXAI	Exscientia PLC
10/06/2024	06:45	PR Newswire (US)	June 25, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against EXAI	NASDAQ:EXAI	Exscientia PLC
06/06/2024	17:16	Business Wire	Exscientia ernennt neue Führungskräfte zur Stärkung der Auswirkungen integrierter Technologien und um den Schwerpunkt auf klinische Entwicklungskompetenz in der Onkologie zu richten	NASDAQ:EXAI	Exscientia PLC